LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

NVS

149.78

+1.28%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

NVS

149.78

+1.28%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

NVS

149.78

+1.28%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

NVS

149.78

+1.28%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

NVS

149.78

+1.28%↑

Search

AbbVie Inc

Cerrado

SectorSanidad

208.54 0.36

Resumen

Variación precio

24h

Actual

Mínimo

204.18

Máximo

209.24

Métricas clave

By Trading Economics

Ingresos

-1.1B

697M

Ventas

-1.6B

15B

P/B

Media del Sector

99.402

51.415

BPA

2.65

Rentabilidad por dividendo

3.34

Margen de beneficios

4.646

Empleados

57,000

EBITDA

-635M

4.7B

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+22.17% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

3.34%

2.34%

Próximas Ganancias

30 jul 2026

Fecha Próximo Dividendo

15 may 2026

Próxima Fecha de Ex Dividendo

14 jul 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

9.2B

358B

Apertura anterior

208.18

Cierre anterior

208.54

Noticias sobre sentimiento de mercado

By Acuity

25%

75%

59 / 346 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

AbbVie Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

29 abr 2026, 12:38 UTC

Ganancias

AbbVie Raises Fiscal Year Guidance on Immunology, Neuroscience Growth

4 feb 2026, 13:20 UTC

Ganancias

AbbVie 4Q Revenue Rises on Immunology Growth

29 abr 2026, 12:41 UTC

Ganancias

AbbVie Beats Earnings Estimates, Boosts 2026 Outlook. What It Means for the Stock. -- Barrons.com

29 abr 2026, 12:23 UTC

Ganancias

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

29 abr 2026, 11:50 UTC

Ganancias

AbbVie Raising Adjusted EPS Guidance for FY26 >ABBV

29 abr 2026, 11:49 UTC

Ganancias

AbbVie 1Q Global Humira Rev $688 M >ABBV

29 abr 2026, 11:48 UTC

Ganancias

AbbVie 1Q Global Rinvoq Rev $2.119 B >ABBV

29 abr 2026, 11:47 UTC

Ganancias

AbbVie 1Q Global Net Rev From Oncology Portfolio $1.63B >ABBV

29 abr 2026, 11:47 UTC

Ganancias

AbbVie 1Q Global Skyrizi Rev $4.48B >ABBV

29 abr 2026, 11:47 UTC

Ganancias

AbbVie 1Q Global IMBRUVICA Rev $556M >ABBV

29 abr 2026, 11:47 UTC

Ganancias

AbbVie 1Q EPS 39c >ABBV

29 abr 2026, 11:47 UTC

Ganancias

AbbVie 1Q Net $695M >ABBV

29 abr 2026, 11:47 UTC

Ganancias

AbbVie 1Q International HUMIRA Rev $331M >ABBV

29 abr 2026, 11:47 UTC

Ganancias

AbbVie 1Q Rev $15B >ABBV

29 abr 2026, 11:47 UTC

Ganancias

AbbVie 1Q Adj EPS $2.65 >ABBV

29 abr 2026, 11:47 UTC

Ganancias

AbbVie 1Q U.S. HUMIRA Rev $357M >ABBV

29 abr 2026, 11:47 UTC

Ganancias

AbbVie Sees FY Adj EPS $14.08-Adj EPS $14.28 >ABBV

4 feb 2026, 19:38 UTC

Ganancias

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

4 feb 2026, 16:19 UTC

Ganancias

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

4 feb 2026, 15:18 UTC

Ganancias

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

4 feb 2026, 13:18 UTC

Ganancias

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

4 feb 2026, 12:48 UTC

Ganancias

AbbVie 4Q U.S. HUMIRA Rev $897M >ABBV

4 feb 2026, 12:48 UTC

Ganancias

AbbVie 4Q Rev $16.62B >ABBV

4 feb 2026, 12:48 UTC

Ganancias

AbbVie 4Q Global IMBRUVICA Rev $671M >ABBV

4 feb 2026, 12:48 UTC

Ganancias

AbbVie 4Q Global Skyrizi Rev $5.01B >ABBV

4 feb 2026, 12:48 UTC

Ganancias

AbbVie 4Q Net $1.82B >ABBV

4 feb 2026, 12:48 UTC

Ganancias

AbbVie 4Q Adj EPS $2.71 >ABBV

4 feb 2026, 12:48 UTC

Ganancias

AbbVie 4Q Global Net Rev From Oncology Portfolio $1.66B >ABBV

4 feb 2026, 12:48 UTC

Ganancias

AbbVie 4Q International HUMIRA Rev $349M >ABBV

4 feb 2026, 12:48 UTC

Ganancias

AbbVie Sees FY Adj EPS $14.37-Adj EPS $14.57 >ABBV

Comparación entre iguales

Cambio de precio

AbbVie Inc previsión

Precio Objetivo

By TipRanks

22.17% repunte

Estimación a 12 Meses

Media 253.94 USD  22.17%

Máximo 294 USD

Mínimo 203 USD

De acuerdo con 20 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AbbVie Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

20 ratings

15

Comprar

5

Mantener

0

Vender

Puntuación técnica

By Trading Central

180.37 / 195.54Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

59 / 346 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
help-icon Live chat